MedTrace Logo

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

NCT04948125 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-07-01

No results posted yet for this study

Summary

This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.

Conditions

  • Advanced Gastric Carcinoma

Interventions

DRUG

camrelizumab

200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.

DRUG

Apatinib Mesylate

250 mg qd

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Ying Liu · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2022-06-03
Completion
2023-08-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948125 on ClinicalTrials.gov